(Q37620374)

21 August 2017

1 reference

title

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents (English)

1 reference

21 August 2017

0 references

0 references

William N Washburn

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Therapeutic Patents

21 August 2017

published in

1 reference

21 August 2017

volume

19

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1485-1499

1 reference

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

Active sugar transport in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

Microvascular complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

Vascular complications in diabetes mellitus: the role of endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903337828

10.1517/13543770903337828

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference